<!DOCTYPE html>
<html>
<head>
    <style>
        .annotation-head {
            padding-top: 7px;
        }

        .annotation-segment, .annotation-head {
            position: relative;
        }

        .anno {
            position: relative;
            text-align: center;
        }

        .label {
            -webkit-border-radius: 3px;
            -moz-border-radius: 3px;
            border-radius: 3px;

            display: inline-block;
            padding: 2px 0;
            font-size: 11.844px;
            font-weight: bold;
            line-height: 14px;
            color: #000000;
            text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.25);
            white-space: nowrap;
            vertical-align: baseline;
            background-color: #999999;
        }

        .marker {
            background: lightgreen;
        }

        .collapsible {
            background-color: #929af0;
            color: #444;
            cursor: pointer;
            padding: 18px;
            width: 100%;
            border: none;
            text-align: left;
            outline: none;
            font-size: 15px;
        }

        .collapsible:hover {
            background-color: #ccc;
        }

        .midcontainer {
            overflow: hidden;
            overflow-x: auto;
            white-space: nowrap;
            margin: 10px;
        }
        .abstractcontainer {
            margin: 10px;
            line-height: 200%;
        }

        .supercontainer {
            border-style: solid;
	        border-width: 1px;
	        border-color: black;
        	border-radius: 3px;
            margin: 10px;
        }
    </style>
    <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.1/jquery.min.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/prototype/1.6.1.0/prototype.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/scriptaculous/1.8.3/scriptaculous.js"
            type="text/javascript"></script>
    <script type="text/javascript">
        (function ($) {
            String.prototype.width = function (font) {

                var f = font || '12px arial',
                    o = $('<div>' + this + '</div>')
                        .css({
                            'position': 'absolute',
                            'float': 'left',
                            'white-space': 'nowrap',
                            'visibility': 'hidden',
                            'font': f
                        })
                        .appendTo($('body')),
                    w = o.width();

                o.remove();

                return w;
            }

            $(document).ready(function () {
                $('.container').each(function () {
                    var c = $(this);
                    $(c).find('.marker').each(function () {
                        var $t = $(this),
                            pos = $t.attr('data-anno-label'),
                            id = $t.attr('head-id'),
                            annoStr = pos;
                        var total_width = 0;
                        $(c).find('.annotation-head .anno').each(function () {
                            total_width += $(this).width();
                        })
                        // create an annotation for each marker
                        var top = this.offsetTop - 5,
                            left = this.offsetLeft - total_width,
                            width = $t.width(),
                            style = 'style="top:' + top + 'px; left:' + left + 'px;width:' + width + 'px;"';

                        $(c).find('.annotation-head').append('<span class="anno label" ' + style + '>' + annoStr + '</span>');
                    });
                })
            });
        })(jQuery);

    </script>
</head>

<body>


<button type="button" class="collapsible">yosi - shaked</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac sodium</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25 g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Patients who had pathologically been proven to have measurable lesions were treated with  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  ( 200 mg/m(2 ) for 3 h ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">carboplatin</span>  [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Patients who had pathologically been proven to have measurable lesions were treated with  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  ( 200 mg/m(2 ) for 3 h ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">carboplatin</span>  [ area under the concentration-time curve ( AUC = 6 ) ] on day 1 and in 21 day cycles . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.</u></h4>The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>pathologically</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>measurable</i></b> <b style='color:DodgerBlue;'><i>lesions</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentration-time</i></b> <b style='color:DodgerBlue;'><i>curve</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. ### conclusions Combination chemotherapy with <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> is feasible in patients with advanced gastric cancer who were previously treated with 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and platinum.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid ,  <span class="marker" data-anno-id="0" data-anno-label="P2/P1">apigenin</span>  , alone and in combination with the antitumor drugs ,  <span class="marker" data-anno-id="1" data-anno-label="P2">cyclophosphamide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">doxorubicin</span>  , in vitro and in vivo . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid ,  <span class="marker" data-anno-id="0" data-anno-label="C1/C2">apigenin</span>  , alone and in combination with the antitumor drugs ,  <span class="marker" data-anno-id="1" data-anno-label="C1">cyclophosphamide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C2">doxorubicin</span>  , in vitro and in vivo . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 μg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 μg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 μg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  With regard to efficacy in metastatic disease , exemestane is superior to megestrol acetate after progression on tamoxifen . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  With regard to efficacy in metastatic disease ,  <span class="marker" data-anno-id="0" data-anno-label="P1">exemestane</span>  is superior to megestrol acetate after progression on  <span class="marker" data-anno-id="1" data-anno-label="P1">tamoxifen</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term efficacy and safety of exemestane in the treatment of breast cancer.</u></h4><b style='color:Tomato;'><i>exemestane</i></b>, a steroidal aromatase inhibitor, is licensed for postmenopausal patients with estrogen receptor (ER)-positive breast cancer as second-line therapy in metastatic disease following antiestrogen failure and as part of sequential adjuvant therapy following initial <b style='color:Tomato;'><i>tamoxifen</i></b>. This study is a systematic literature review, evaluating <b style='color:Tomato;'><i>exemestane</i></b> in different clinical settings. The Ovid Medline (1948-2012), Embase (1980-2012), and Web of Science (1899-2012) databases were searched. Forty-two relevant articles covering randomized controlled trials were reviewed for efficacy and safety, and three for adherence. <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>regard</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>megestrol</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There is evidence for noninferiority to <b style='color:Tomato;'><i>fulvestrant</i></b> (following a prior aromatase inhibitor) and to nonsteroidal aromatase inhibitors in the first-line setting. Combined use with <b style='color:Tomato;'><i>everolimus</i></b> is shown to be more efficacious than <b style='color:Tomato;'><i>exemestane</i></b> alone following previous aromatase inhibitor use. In the adjuvant setting, a switch to <b style='color:Tomato;'><i>exemestane</i></b> after 2-3 years of <b style='color:Tomato;'><i>tamoxifen</i></b> is superior to 5 years of <b style='color:Tomato;'><i>tamoxifen</i></b>. <b style='color:Tomato;'><i>exemestane</i></b> is noninferior to 5 years of <b style='color:Tomato;'><i>tamoxifen</i></b> as upfront therapy, and may have a role as an extended adjuvant therapy. Used as neoadjuvant therapy, increased breast conservation is achievable. As chemoprevention, <b style='color:Tomato;'><i>exemestane</i></b> significantly reduces the incidence of breast cancer in "at-risk" postmenopausal women. <b style='color:Tomato;'><i>exemestane</i></b> is associated with myalgias and arthralgias, as well as reduced bone mineral density and increased risk of fracture, which do not appear to persist at follow-up, with subsequent return to pretreatment values. Compared with <b style='color:Tomato;'><i>tamoxifen</i></b>, there is a reduced incidence of endometrial changes, thromboembolic events, and hot flashes. Limited evidence shows nonadherence in 23%-32% of patients. Evidence is growing in support of <b style='color:Tomato;'><i>exemestane</i></b> in all clinical settings. It is generally more efficacious and has a better safety profile than <b style='color:Tomato;'><i>tamoxifen</i></b>. How it compares with the nonsteroidal aromatase inhibitors remains to be established. Further studies are required on adherence to ensure that maximum benefit is obtained.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Phase Ib Study of the Oral Proteasome Inhibitor  <span class="marker" data-anno-id="0" data-anno-label="P1">Ixazomib</span>  ( MLN9708 ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">Fulvestrant</span>  in Advanced ER+ Breast Cancer Progressing on Fulvestrant . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Phase Ib Study of the Oral Proteasome Inhibitor  <span class="marker" data-anno-id="0" data-anno-label="P1">Ixazomib</span>  ( MLN9708 ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">Fulvestrant</span>  in Advanced ER+ Breast Cancer Progressing on  <span class="marker" data-anno-id="2" data-anno-label="P1">Fulvestrant</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Oral</i></b> <b style='color:DodgerBlue;'><i>Proteasome</i></b> <b style='color:DodgerBlue;'><i>Inhibitor</i></b> <b style='color:MediumOrchid;'><i>Ixazomib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MLN9708</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>ER+</i></b> <b style='color:DodgerBlue;'><i>Breast</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>Progressing</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>Fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h4><b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### background <b style='color:Tomato;'><i>fulvestrant</i></b> is a selective estrogen receptor (ER)-downregulating anti-estrogen that blocks ER transcriptional activity and is approved for ER+ breast cancer. <b style='color:Tomato;'><i>fulvestrant</i></b> also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitors have been shown to enhance these effects in preclinical models. ### methods This is a single-center phase Ib study with a 3+3 design of <b style='color:Tomato;'><i>fulvestrant</i></b> and the proteasome inhibitor <b style='color:Tomato;'><i>ixazomib</i></b> (MLN9708) in patients with advanced ER+ breast cancer that was progressing on <b style='color:Tomato;'><i>fulvestrant</i></b>. A dose-escalation design allowed establishment of the <b style='color:Tomato;'><i>ixazomib</i></b> maximum tolerated dose (MTD). Secondary objectives included progression-free survival, pharmacokinetics, and tumor molecular analyses. ### results Among nine evaluable subjects, treatment was well-tolerated without dose-limiting toxicities The MTD of <b style='color:Tomato;'><i>ixazomib</i></b> was 4 mg in combination with <b style='color:Tomato;'><i>fulvestrant</i></b>. Plasma concentrations of the active form of <b style='color:Tomato;'><i>ixazomib</i></b> (MLN2238) in the 4-mg dose cohort had a median (range) Cmax of 155 (122-171) ng/mL; Tmax of 1 (1-1.5) h; terminal elimination half-life of 66.6 (57.3-102.6) hr after initial dose; AUC of 5,025 (4,160-5,345) ng*h/mL. One partial response was observed, and median progression-free survival was 51 days (range 47-137). ### conclusion This drug combination has a favorable safety profile and anti-tumor activity in patients with <b style='color:Tomato;'><i>fulvestrant</i></b>-resistant advanced ER+ breast cancer that justifies future testing.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Both paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) and ifosfamide have been demonstrated to be active agents in patients with clinically defined platinum-refractory ovarian cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Shaked:</b>  Both  <span class="marker" data-anno-id="0" data-anno-label="P1">paclitaxel</span>  ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) and  <span class="marker" data-anno-id="1" data-anno-label="P1">ifosfamide</span>  have been demonstrated to be active agents in patients with clinically defined platinum-refractory ovarian cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.</u></h4> <b style='color:DodgerBlue;'><i>Both</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>clinically</i></b> <b style='color:DodgerBlue;'><i>defined</i></b> <b style='color:DodgerBlue;'><i>platinum-refractory</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> While there might be interest in combining these two drugs as salvage therapy for this disease, the recent inclusion of <b style='color:Tomato;'><i>paclitaxel</i></b> as initial therapy for advanced ovarian cancer, along with a platinum agent (cisplatin or <b style='color:Tomato;'><i>carboplatin</i></b>), makes it unlikely that <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>ifosfamide</i></b> will be used clinically in this malignancy. However, if alkylating agents are not to be used as part of the initial chemotherapy strategy for women with advanced ovarian cancer, it will be important to evaluate the activity of <b style='color:Tomato;'><i>ifosfamide</i></b> as salvage therapy in individuals treated only with, and demonstrated to be refractory to, a platinum agent and <b style='color:Tomato;'><i>paclitaxel</i></b>. If significant activity for <b style='color:Tomato;'><i>ifosfamide</i></b> is observed in this clinical setting, evaluation of the potential utility of a three-drug combination regimen comprising <b style='color:Tomato;'><i>ifosfamide</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, and cisplatin or <b style='color:Tomato;'><i>carboplatin</i></b> may be quite relevant.</div></div></div></div><button type="button" class="collapsible">yosi - hagit</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="N1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="N1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25 g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Correlation of lidocaine induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral oxybutynin was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Correlation of  <span class="marker" data-anno-id="0" data-anno-label="P1">lidocaine</span>  induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral  <span class="marker" data-anno-id="1" data-anno-label="P1">oxybutynin</span>  was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effects of intravesical lidocaine on bladder dynamics of children with myelomeningocele.</u></h4>Other studies have suggested that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> may temporarily improve bladder dynamics but details of these effects and their application to children have not been examined. We evaluated the effects of intravesical <b style='color:Tomato;'><i>lidocaine</i></b> on bladder urodynamics of children with myelomeningocele and tried to correlate these effects with subsequent clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b>. ### Materials And Methods Charts of children with myelomeningocele who had undergone urodynamic examinations from 1992 to 1998 were reviewed retrospectively. In children with uninhibited contractions or poor compliance 150 to 300 mg. <b style='color:Tomato;'><i>lidocaine</i></b> were instilled for 8 minutes and cystometry was repeated. Changes in bladder capacity and compliance, number of uninhibited contractions and bladder volume at which pressure of 40 cm. H2O was reached were recorded before and after the <b style='color:Tomato;'><i>lidocaine</i></b> instillation. Clinical response to subsequent treatment with oral <b style='color:Tomato;'><i>oxybutynin</i></b> was assessed from chart review. ### results A total of 48 urodynamic studies in 22 girls and 20 boys with a mean age plus or minus standard deviation of 8.3 +/- 5.7 years and myelomeningocele were evaluable. After instillation of <b style='color:Tomato;'><i>lidocaine</i></b>, urodynamics showed increased bladder capacity in 70.8% of studies (34 of 48), with an average increase in volume of 66% (p <0.05). No change or decreased bladder capacity occurred in 29.2% of studies. Bladder compliance improved in 61.7% of the studies (29 of 47, p <0.05) and worsened in 38.3%. Bladder volume at which the pressure of 40 cm. H2O was reached increased in 77.8% of studies (14 of 18, p <0.05). After <b style='color:Tomato;'><i>lidocaine</i></b> the number of uninhibited contractions decreased by 3.2 in 56.8% of studies (21 of 37, p <0.05). <b style='color:DodgerBlue;'><i>Correlation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>capacity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compliance</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>uninhibited</i></b> <b style='color:DodgerBlue;'><i>contractions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>oxybutynin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>70.6</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>64.3</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>66.7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Intravesical <b style='color:Tomato;'><i>lidocaine</i></b> can improve bladder capacity and compliance and decrease the number of uninhibited contractions in many children with neurogenic bladder caused by myelomeningocele. These observations suggest that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> has effects on the neurogenic bladder that improve bladder dynamics. Although intravesical <b style='color:Tomato;'><i>lidocaine</i></b> testing may not reliably predict clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b> at the prescribed dosages, a possible therapeutic role for intravesical <b style='color:Tomato;'><i>lidocaine</i></b> or similar agents should be explored further.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid ,  <span class="marker" data-anno-id="0" data-anno-label="P2/P1">apigenin</span>  , alone and in combination with the antitumor drugs ,  <span class="marker" data-anno-id="1" data-anno-label="P2">cyclophosphamide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">doxorubicin</span>  , in vitro and in vivo . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid ,  <span class="marker" data-anno-id="0" data-anno-label="P1/C1">apigenin</span>  , alone and in combination with the antitumor drugs ,  <span class="marker" data-anno-id="1" data-anno-label="P1">cyclophosphamide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">doxorubicin</span>  , in vitro and in vivo . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 μg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 μg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 μg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  With regard to efficacy in metastatic disease , exemestane is superior to megestrol acetate after progression on tamoxifen . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  With regard to efficacy in metastatic disease ,  <span class="marker" data-anno-id="0" data-anno-label="P1">exemestane</span>  is superior to  <span class="marker" data-anno-id="1" data-anno-label="C1">megestrol</span>  acetate after progression on  <span class="marker" data-anno-id="2" data-anno-label="C1/P1">tamoxifen</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term efficacy and safety of exemestane in the treatment of breast cancer.</u></h4><b style='color:Tomato;'><i>exemestane</i></b>, a steroidal aromatase inhibitor, is licensed for postmenopausal patients with estrogen receptor (ER)-positive breast cancer as second-line therapy in metastatic disease following antiestrogen failure and as part of sequential adjuvant therapy following initial <b style='color:Tomato;'><i>tamoxifen</i></b>. This study is a systematic literature review, evaluating <b style='color:Tomato;'><i>exemestane</i></b> in different clinical settings. The Ovid Medline (1948-2012), Embase (1980-2012), and Web of Science (1899-2012) databases were searched. Forty-two relevant articles covering randomized controlled trials were reviewed for efficacy and safety, and three for adherence. <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>regard</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>megestrol</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There is evidence for noninferiority to <b style='color:Tomato;'><i>fulvestrant</i></b> (following a prior aromatase inhibitor) and to nonsteroidal aromatase inhibitors in the first-line setting. Combined use with <b style='color:Tomato;'><i>everolimus</i></b> is shown to be more efficacious than <b style='color:Tomato;'><i>exemestane</i></b> alone following previous aromatase inhibitor use. In the adjuvant setting, a switch to <b style='color:Tomato;'><i>exemestane</i></b> after 2-3 years of <b style='color:Tomato;'><i>tamoxifen</i></b> is superior to 5 years of <b style='color:Tomato;'><i>tamoxifen</i></b>. <b style='color:Tomato;'><i>exemestane</i></b> is noninferior to 5 years of <b style='color:Tomato;'><i>tamoxifen</i></b> as upfront therapy, and may have a role as an extended adjuvant therapy. Used as neoadjuvant therapy, increased breast conservation is achievable. As chemoprevention, <b style='color:Tomato;'><i>exemestane</i></b> significantly reduces the incidence of breast cancer in "at-risk" postmenopausal women. <b style='color:Tomato;'><i>exemestane</i></b> is associated with myalgias and arthralgias, as well as reduced bone mineral density and increased risk of fracture, which do not appear to persist at follow-up, with subsequent return to pretreatment values. Compared with <b style='color:Tomato;'><i>tamoxifen</i></b>, there is a reduced incidence of endometrial changes, thromboembolic events, and hot flashes. Limited evidence shows nonadherence in 23%-32% of patients. Evidence is growing in support of <b style='color:Tomato;'><i>exemestane</i></b> in all clinical settings. It is generally more efficacious and has a better safety profile than <b style='color:Tomato;'><i>tamoxifen</i></b>. How it compares with the nonsteroidal aromatase inhibitors remains to be established. Further studies are required on adherence to ensure that maximum benefit is obtained.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Both paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) and ifosfamide have been demonstrated to be active agents in patients with clinically defined platinum-refractory ovarian cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Hagit:</b>  Both  <span class="marker" data-anno-id="0" data-anno-label="C1">paclitaxel</span>  ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) and  <span class="marker" data-anno-id="1" data-anno-label="C1">ifosfamide</span>  have been demonstrated to be active agents in patients with clinically defined platinum-refractory ovarian cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.</u></h4> <b style='color:DodgerBlue;'><i>Both</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Taxol</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>Bristol-Myers</i></b> <b style='color:DodgerBlue;'><i>Squibb</i></b> <b style='color:DodgerBlue;'><i>Company</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Princeton</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>NJ</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>clinically</i></b> <b style='color:DodgerBlue;'><i>defined</i></b> <b style='color:DodgerBlue;'><i>platinum-refractory</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> While there might be interest in combining these two drugs as salvage therapy for this disease, the recent inclusion of <b style='color:Tomato;'><i>paclitaxel</i></b> as initial therapy for advanced ovarian cancer, along with a platinum agent (cisplatin or <b style='color:Tomato;'><i>carboplatin</i></b>), makes it unlikely that <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>ifosfamide</i></b> will be used clinically in this malignancy. However, if alkylating agents are not to be used as part of the initial chemotherapy strategy for women with advanced ovarian cancer, it will be important to evaluate the activity of <b style='color:Tomato;'><i>ifosfamide</i></b> as salvage therapy in individuals treated only with, and demonstrated to be refractory to, a platinum agent and <b style='color:Tomato;'><i>paclitaxel</i></b>. If significant activity for <b style='color:Tomato;'><i>ifosfamide</i></b> is observed in this clinical setting, evaluation of the potential utility of a three-drug combination regimen comprising <b style='color:Tomato;'><i>ifosfamide</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, and cisplatin or <b style='color:Tomato;'><i>carboplatin</i></b> may be quite relevant.</div></div></div></div><button type="button" class="collapsible">yosi - dana_n</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Correlation of lidocaine induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral oxybutynin was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Correlation of  <span class="marker" data-anno-id="0" data-anno-label="P1">lidocaine</span>  induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral  <span class="marker" data-anno-id="1" data-anno-label="P1">oxybutynin</span>  was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effects of intravesical lidocaine on bladder dynamics of children with myelomeningocele.</u></h4>Other studies have suggested that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> may temporarily improve bladder dynamics but details of these effects and their application to children have not been examined. We evaluated the effects of intravesical <b style='color:Tomato;'><i>lidocaine</i></b> on bladder urodynamics of children with myelomeningocele and tried to correlate these effects with subsequent clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b>. ### Materials And Methods Charts of children with myelomeningocele who had undergone urodynamic examinations from 1992 to 1998 were reviewed retrospectively. In children with uninhibited contractions or poor compliance 150 to 300 mg. <b style='color:Tomato;'><i>lidocaine</i></b> were instilled for 8 minutes and cystometry was repeated. Changes in bladder capacity and compliance, number of uninhibited contractions and bladder volume at which pressure of 40 cm. H2O was reached were recorded before and after the <b style='color:Tomato;'><i>lidocaine</i></b> instillation. Clinical response to subsequent treatment with oral <b style='color:Tomato;'><i>oxybutynin</i></b> was assessed from chart review. ### results A total of 48 urodynamic studies in 22 girls and 20 boys with a mean age plus or minus standard deviation of 8.3 +/- 5.7 years and myelomeningocele were evaluable. After instillation of <b style='color:Tomato;'><i>lidocaine</i></b>, urodynamics showed increased bladder capacity in 70.8% of studies (34 of 48), with an average increase in volume of 66% (p <0.05). No change or decreased bladder capacity occurred in 29.2% of studies. Bladder compliance improved in 61.7% of the studies (29 of 47, p <0.05) and worsened in 38.3%. Bladder volume at which the pressure of 40 cm. H2O was reached increased in 77.8% of studies (14 of 18, p <0.05). After <b style='color:Tomato;'><i>lidocaine</i></b> the number of uninhibited contractions decreased by 3.2 in 56.8% of studies (21 of 37, p <0.05). <b style='color:DodgerBlue;'><i>Correlation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>capacity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compliance</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>uninhibited</i></b> <b style='color:DodgerBlue;'><i>contractions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>oxybutynin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>70.6</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>64.3</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>66.7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Intravesical <b style='color:Tomato;'><i>lidocaine</i></b> can improve bladder capacity and compliance and decrease the number of uninhibited contractions in many children with neurogenic bladder caused by myelomeningocele. These observations suggest that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> has effects on the neurogenic bladder that improve bladder dynamics. Although intravesical <b style='color:Tomato;'><i>lidocaine</i></b> testing may not reliably predict clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b> at the prescribed dosages, a possible therapeutic role for intravesical <b style='color:Tomato;'><i>lidocaine</i></b> or similar agents should be explored further.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with  <span class="marker" data-anno-id="0" data-anno-label="N1">bevacizumab</span>  ( 5 mg/kg body weight i.v . every 21 days ) and oral  <span class="marker" data-anno-id="1" data-anno-label="N1">capecitabine</span>  ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with  <span class="marker" data-anno-id="0" data-anno-label="C1">bevacizumab</span>  ( 5 mg/kg body weight i.v . every 21 days ) and oral  <span class="marker" data-anno-id="1" data-anno-label="C1">capecitabine</span>  ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h4>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_n:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div></div><button type="button" class="collapsible">yosi - dana_a</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="N1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="N1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25 g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Dana_a:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div></div><button type="button" class="collapsible">yosi - maytal</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="N1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="N1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25 g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Correlation of lidocaine induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral oxybutynin was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Correlation of  <span class="marker" data-anno-id="0" data-anno-label="C1">lidocaine</span>  induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral  <span class="marker" data-anno-id="1" data-anno-label="C1">oxybutynin</span>  was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effects of intravesical lidocaine on bladder dynamics of children with myelomeningocele.</u></h4>Other studies have suggested that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> may temporarily improve bladder dynamics but details of these effects and their application to children have not been examined. We evaluated the effects of intravesical <b style='color:Tomato;'><i>lidocaine</i></b> on bladder urodynamics of children with myelomeningocele and tried to correlate these effects with subsequent clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b>. ### Materials And Methods Charts of children with myelomeningocele who had undergone urodynamic examinations from 1992 to 1998 were reviewed retrospectively. In children with uninhibited contractions or poor compliance 150 to 300 mg. <b style='color:Tomato;'><i>lidocaine</i></b> were instilled for 8 minutes and cystometry was repeated. Changes in bladder capacity and compliance, number of uninhibited contractions and bladder volume at which pressure of 40 cm. H2O was reached were recorded before and after the <b style='color:Tomato;'><i>lidocaine</i></b> instillation. Clinical response to subsequent treatment with oral <b style='color:Tomato;'><i>oxybutynin</i></b> was assessed from chart review. ### results A total of 48 urodynamic studies in 22 girls and 20 boys with a mean age plus or minus standard deviation of 8.3 +/- 5.7 years and myelomeningocele were evaluable. After instillation of <b style='color:Tomato;'><i>lidocaine</i></b>, urodynamics showed increased bladder capacity in 70.8% of studies (34 of 48), with an average increase in volume of 66% (p <0.05). No change or decreased bladder capacity occurred in 29.2% of studies. Bladder compliance improved in 61.7% of the studies (29 of 47, p <0.05) and worsened in 38.3%. Bladder volume at which the pressure of 40 cm. H2O was reached increased in 77.8% of studies (14 of 18, p <0.05). After <b style='color:Tomato;'><i>lidocaine</i></b> the number of uninhibited contractions decreased by 3.2 in 56.8% of studies (21 of 37, p <0.05). <b style='color:DodgerBlue;'><i>Correlation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>capacity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compliance</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>uninhibited</i></b> <b style='color:DodgerBlue;'><i>contractions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>oxybutynin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>70.6</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>64.3</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>66.7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Intravesical <b style='color:Tomato;'><i>lidocaine</i></b> can improve bladder capacity and compliance and decrease the number of uninhibited contractions in many children with neurogenic bladder caused by myelomeningocele. These observations suggest that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> has effects on the neurogenic bladder that improve bladder dynamics. Although intravesical <b style='color:Tomato;'><i>lidocaine</i></b> testing may not reliably predict clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b> at the prescribed dosages, a possible therapeutic role for intravesical <b style='color:Tomato;'><i>lidocaine</i></b> or similar agents should be explored further.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with  <span class="marker" data-anno-id="0" data-anno-label="N1">bevacizumab</span>  ( 5 mg/kg body weight i.v . every 21 days ) and oral  <span class="marker" data-anno-id="1" data-anno-label="N1">capecitabine</span>  ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with  <span class="marker" data-anno-id="0" data-anno-label="C1">bevacizumab</span>  ( 5 mg/kg body weight i.v . every 21 days ) and oral  <span class="marker" data-anno-id="1" data-anno-label="C1">capecitabine</span>  ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h4>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi__:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Maytal:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div></div><button type="button" class="collapsible">yosi - yuval</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac sodium</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25 g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Correlation of lidocaine induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral oxybutynin was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Correlation of  <span class="marker" data-anno-id="0" data-anno-label="P1">lidocaine</span>  induced changes in bladder capacity , compliance and number of uninhibited contractions with improvement on oral  <span class="marker" data-anno-id="1" data-anno-label="P1">oxybutynin</span>  was 70.6 % , 64.3 % and 66.7 % , respectively . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effects of intravesical lidocaine on bladder dynamics of children with myelomeningocele.</u></h4>Other studies have suggested that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> may temporarily improve bladder dynamics but details of these effects and their application to children have not been examined. We evaluated the effects of intravesical <b style='color:Tomato;'><i>lidocaine</i></b> on bladder urodynamics of children with myelomeningocele and tried to correlate these effects with subsequent clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b>. ### Materials And Methods Charts of children with myelomeningocele who had undergone urodynamic examinations from 1992 to 1998 were reviewed retrospectively. In children with uninhibited contractions or poor compliance 150 to 300 mg. <b style='color:Tomato;'><i>lidocaine</i></b> were instilled for 8 minutes and cystometry was repeated. Changes in bladder capacity and compliance, number of uninhibited contractions and bladder volume at which pressure of 40 cm. H2O was reached were recorded before and after the <b style='color:Tomato;'><i>lidocaine</i></b> instillation. Clinical response to subsequent treatment with oral <b style='color:Tomato;'><i>oxybutynin</i></b> was assessed from chart review. ### results A total of 48 urodynamic studies in 22 girls and 20 boys with a mean age plus or minus standard deviation of 8.3 +/- 5.7 years and myelomeningocele were evaluable. After instillation of <b style='color:Tomato;'><i>lidocaine</i></b>, urodynamics showed increased bladder capacity in 70.8% of studies (34 of 48), with an average increase in volume of 66% (p <0.05). No change or decreased bladder capacity occurred in 29.2% of studies. Bladder compliance improved in 61.7% of the studies (29 of 47, p <0.05) and worsened in 38.3%. Bladder volume at which the pressure of 40 cm. H2O was reached increased in 77.8% of studies (14 of 18, p <0.05). After <b style='color:Tomato;'><i>lidocaine</i></b> the number of uninhibited contractions decreased by 3.2 in 56.8% of studies (21 of 37, p <0.05). <b style='color:DodgerBlue;'><i>Correlation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>capacity</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>compliance</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>uninhibited</i></b> <b style='color:DodgerBlue;'><i>contractions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>oxybutynin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>70.6</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>64.3</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>66.7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Intravesical <b style='color:Tomato;'><i>lidocaine</i></b> can improve bladder capacity and compliance and decrease the number of uninhibited contractions in many children with neurogenic bladder caused by myelomeningocele. These observations suggest that intravesical <b style='color:Tomato;'><i>lidocaine</i></b> has effects on the neurogenic bladder that improve bladder dynamics. Although intravesical <b style='color:Tomato;'><i>lidocaine</i></b> testing may not reliably predict clinical response to oral <b style='color:Tomato;'><i>oxybutynin</i></b> at the prescribed dosages, a possible therapeutic role for intravesical <b style='color:Tomato;'><i>lidocaine</i></b> or similar agents should be explored further.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Eligible patients received  <span class="marker" data-anno-id="0" data-anno-label="P1">ramucirumab</span>  ( 10mg/kg ) +  <span class="marker" data-anno-id="1" data-anno-label="P1">dacarbazine</span>  ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  Eligible patients received ramucirumab ( 10mg/kg ) +  <span class="marker" data-anno-id="0" data-anno-label="P1">dacarbazine</span>  ( 1000 mg/m(2 ) ) ( Arm A ) or  <span class="marker" data-anno-id="1" data-anno-label="P1">ramucirumab</span>  only ( 10mg/kg ) ( Arm B ) every 3 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h4>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-naïve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  With regard to efficacy in metastatic disease , exemestane is superior to megestrol acetate after progression on tamoxifen . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yuval:</b>  With regard to efficacy in metastatic disease ,  <span class="marker" data-anno-id="0" data-anno-label="P1">exemestane</span>  is superior to  <span class="marker" data-anno-id="1" data-anno-label="N1">megestrol</span>  acetate after progression on  <span class="marker" data-anno-id="2" data-anno-label="N1/P1">tamoxifen</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Long-term efficacy and safety of exemestane in the treatment of breast cancer.</u></h4><b style='color:Tomato;'><i>exemestane</i></b>, a steroidal aromatase inhibitor, is licensed for postmenopausal patients with estrogen receptor (ER)-positive breast cancer as second-line therapy in metastatic disease following antiestrogen failure and as part of sequential adjuvant therapy following initial <b style='color:Tomato;'><i>tamoxifen</i></b>. This study is a systematic literature review, evaluating <b style='color:Tomato;'><i>exemestane</i></b> in different clinical settings. The Ovid Medline (1948-2012), Embase (1980-2012), and Web of Science (1899-2012) databases were searched. Forty-two relevant articles covering randomized controlled trials were reviewed for efficacy and safety, and three for adherence. <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>regard</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>superior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>megestrol</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There is evidence for noninferiority to <b style='color:Tomato;'><i>fulvestrant</i></b> (following a prior aromatase inhibitor) and to nonsteroidal aromatase inhibitors in the first-line setting. Combined use with <b style='color:Tomato;'><i>everolimus</i></b> is shown to be more efficacious than <b style='color:Tomato;'><i>exemestane</i></b> alone following previous aromatase inhibitor use. In the adjuvant setting, a switch to <b style='color:Tomato;'><i>exemestane</i></b> after 2-3 years of <b style='color:Tomato;'><i>tamoxifen</i></b> is superior to 5 years of <b style='color:Tomato;'><i>tamoxifen</i></b>. <b style='color:Tomato;'><i>exemestane</i></b> is noninferior to 5 years of <b style='color:Tomato;'><i>tamoxifen</i></b> as upfront therapy, and may have a role as an extended adjuvant therapy. Used as neoadjuvant therapy, increased breast conservation is achievable. As chemoprevention, <b style='color:Tomato;'><i>exemestane</i></b> significantly reduces the incidence of breast cancer in "at-risk" postmenopausal women. <b style='color:Tomato;'><i>exemestane</i></b> is associated with myalgias and arthralgias, as well as reduced bone mineral density and increased risk of fracture, which do not appear to persist at follow-up, with subsequent return to pretreatment values. Compared with <b style='color:Tomato;'><i>tamoxifen</i></b>, there is a reduced incidence of endometrial changes, thromboembolic events, and hot flashes. Limited evidence shows nonadherence in 23%-32% of patients. Evidence is growing in support of <b style='color:Tomato;'><i>exemestane</i></b> in all clinical settings. It is generally more efficacious and has a better safety profile than <b style='color:Tomato;'><i>tamoxifen</i></b>. How it compares with the nonsteroidal aromatase inhibitors remains to be established. Further studies are required on adherence to ensure that maximum benefit is obtained.</div></div></div></div><button type="button" class="collapsible">yosi - yakir</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  We determined the effects of  <span class="marker" data-anno-id="0" data-anno-label="C1">diclofenac</span>  sodium ,  <span class="marker" data-anno-id="1" data-anno-label="C1">octreotide</span>  , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  We determined the effects of diclofenac sodium , octreotide , and their combination on extrapancreatic organ injuries in caerulein-induced acute pancreatitis in mice . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Diclofenac Sodium Treatment Ameliorates Extrapancreatic Organ Injuries in a Murine Model of Acute Pancreatitis Induced by Caerulein.</u></h4> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>determined</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>diclofenac</i></b> <b style='color:DodgerBlue;'><i>sodium</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>octreotide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>extrapancreatic</i></b> <b style='color:DodgerBlue;'><i>organ</i></b> <b style='color:DodgerBlue;'><i>injuries</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>caerulein-induced</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>pancreatitis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A total of 58 BALB-C male mice (25 g) were divided into seven groups and used to create a caerulein-induced acute pancreatitis model. <b style='color:Tomato;'><i>diclofenac</i></b> sodium, <b style='color:Tomato;'><i>octreotide</i></b>, and their combination were given for treatment of caerulin-induced acute pancreatitis in mice. At the end of the experiment, the lung, liver, kidney, and stomach were removed for histopathologic assessment. ### results Histopathologic investigation revealed a statistically significant difference between the groups in mean congestion, edema, tubular injury, perirenal fat tissue inflammation, and tubular stasis scores in kidney tissue ( ### conclusion <b style='color:Tomato;'><i>diclofenac</i></b> sodium alone ameliorates lung edema due to caerulin-induced acute pancreatitis.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Eligible patients received  <span class="marker" data-anno-id="0" data-anno-label="P1">ramucirumab</span>  ( 10mg/kg ) +  <span class="marker" data-anno-id="1" data-anno-label="P1">dacarbazine</span>  ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Eligible patients received ramucirumab ( 10mg/kg ) + dacarbazine ( 1000 mg/m(2 ) ) ( Arm A ) or ramucirumab only ( 10mg/kg ) ( Arm B ) every 3 weeks . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.</u></h4>To evaluate the efficacy and safety of <b style='color:Tomato;'><i>ramucirumab</i></b> (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> in chemotherapy-naïve patients with metastatic melanoma (MM). ### methods <b style='color:DodgerBlue;'><i>Eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ramucirumab</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Arm</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. ### findings Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. ### interpretation <b style='color:Tomato;'><i>ramucirumab</i></b> alone or in combination with <b style='color:Tomato;'><i>dacarbazine</i></b> was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with  <span class="marker" data-anno-id="0" data-anno-label="N1">bevacizumab</span>  ( 5 mg/kg body weight i.v . every 21 days ) and oral  <span class="marker" data-anno-id="1" data-anno-label="N1">capecitabine</span>  ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab ( 5 mg/kg body weight i.v . every 21 days ) and oral capecitabine ( 950 mg/m(2 ) twice daily for 14 days followed by 7 days of rest ) in 2006 - 2008 . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.</u></h4>No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended <b style='color:Tomato;'><i>mitotane</i></b> as monotherapy or combined with <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin or with <b style='color:Tomato;'><i>streptozotocin</i></b> as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> as salvage therapy in ACC. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>registered</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>German</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>Registry</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>offered</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>body</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>950</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>twice</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>14</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>rest</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>2006</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2008</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. ### results Ten patients were treated with <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b>. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. ### conclusions <b style='color:Tomato;'><i>bevacizumab</i></b> plus <b style='color:Tomato;'><i>capecitabine</i></b> has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Drug exposure of mesenchymal HCC cells showed higher resistance to the targeted therapeutic agents sorafenib and erlotinib as compared to epithelial HCC cells , which were slightly more resistant to cytostatic drugs . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Drug exposure of mesenchymal HCC cells showed higher resistance to the targeted therapeutic agents  <span class="marker" data-anno-id="0" data-anno-label="P2">sorafenib</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P2">erlotinib</span>  as compared to epithelial HCC cells , which were slightly more resistant to cytostatic drugs . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression.</u></h4>The epithelial to mesenchymal transition (EMT) of malignant hepatocytes is a crucial event in hepatocellular carcinoma (HCC) progression and recurrence. We aimed to establish a human model of EMT to examine drug efficacy and specificity in HCC progression. Human HCC cell populations were characterized by immunofluorescence analysis, migration and invasion assays, array comparative genomic hybridization, whole-genome expression profiling, and promoter methylation. Therapeutic agents clinically used against HCC were examined for efficacy by determination of IC(50) values. We show that liver cancer cell lines exhibited either an epithelial or mesenchymal phenotype of which the latter showed strong migratory and invasive abilities in vitro. The common cellular origin of both cell types indicated that mesenchymal HCC cells have been derived from epithelial hepatocytes through EMT in the HCC patient. <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>exposure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mesenchymal</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>targeted</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>slightly</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>cytostatic</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most remarkably, combined treatment with <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>sorafenib</i></b> caused increased susceptibility of both HCC cell types resulting in enhanced drug efficacy. Taken together, this EMT model of human HCC allows the identification of molecular mechanisms and the assessment of therapeutic drug efficacy during liver cancer progression in preclinical studies.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid ,  <span class="marker" data-anno-id="0" data-anno-label="P2/P1">apigenin</span>  , alone and in combination with the antitumor drugs ,  <span class="marker" data-anno-id="1" data-anno-label="P2">cyclophosphamide</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">doxorubicin</span>  , in vitro and in vivo . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  The aim of this study was to investigate the mutagenic and antigenotoxic effects of different doses of the flavonoid , apigenin , alone and in combination with the antitumor drugs , cyclophosphamide and doxorubicin , in vitro and in vivo . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The effect of apigenin on cyclophosphamide and doxorubicin genotoxicity in vitro and in vivo.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mutagenic</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>antigenotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>flavonoid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>apigenin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Using bacterial reverse mutation inhibition in vitro, with and without metabolic activation, the effect of apigenin (10-400 μg/plate) was studied on genotoxicity induced by <b style='color:Tomato;'><i>cyclophosphamide</i></b> (800 μg/plate) and by <b style='color:Tomato;'><i>doxorubicin</i></b> (0.2 μg/plate). Subsequent to a dose-finding study in vivo, CD1 mice were treated with either <b style='color:Tomato;'><i>cyclophosphamide</i></b> (40 mg/kg, i.p.) or <b style='color:Tomato;'><i>doxorubicin</i></b> (5 mg/kg, i.p.) with or without co-administration of apigenin (1-100 mg/kg, p.o.). Micronuclei were determined microscopically in blood smears and glutathione peroxidase (GPX), superoxide dismutase (SOD) and total antioxidative status (TAS) in whole blood, erythrocytes and plasma, respectively. Apigenin decreased <b style='color:Tomato;'><i>doxorubicin</i></b>-induced, but not <b style='color:Tomato;'><i>cyclophosphamide</i></b>-induced mutagenicity in vitro. In vivo, apigenin caused a statistically significant decrease in micronucleus frequency in response to <b style='color:Tomato;'><i>cyclophosphamide</i></b>, possibly due to active flavonoid metabolite formation or inhibition of <b style='color:Tomato;'><i>cyclophosphamide</i></b> metabolic activation. In animals treated with apigenin and <b style='color:Tomato;'><i>doxorubicin</i></b>, a significant decrease in micronucleus frequency was not observed, probably due to interindividual variability. No changes in GPX, SOD or TAS were observed in response to either cytotoxic agents or the flavonoid, possibly due to limited metabolic transformation of the drugs at the doses used. The results of the present study provide further evidence for the chemo-preventative properties of apigenin.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and fluorouracil ( TPF ) for treating metastatic SCCE . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  More effective regimens are urgently needed for squamous cell carcinoma of esophagus ( SCCE ) , therefore , we conducted a phase I/II trial of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">docetaxel</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">platinum</span>  , and  <span class="marker" data-anno-id="2" data-anno-label="P1">fluorouracil</span>  ( TPF ) for treating metastatic SCCE . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.</u></h4> <b style='color:DodgerBlue;'><i>More</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>urgently</i></b> <b style='color:DodgerBlue;'><i>needed</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>squamous</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>esophagus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I/II</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TPF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treating</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>SCCE</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This phase I/II trial (n = 12/39) was conducted in our institute from April 2005 to June 2008. Progression-free survival (PFS) and overall survival were analyzed by the Kaplan-Meier method. ### results The recommended dose of <b style='color:Tomato;'><i>docetaxel</i></b> was determined to be 50 mg/m in phase I. In phase II with a mean follow-up period of 13.3 months, the objective response rate was 66.6%, a median survival period of 13 months and PFS of 7 months was achieved, and the 1-year survival and PFS rates were 52.9% and 19.6%, respectively. Grade 3/4 toxicities of leukopenia, neutropenia, and anorexia were observed in 53.8%, 43.6%, and 25.6%, respectively. ### conclusions A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens. Randomized phase III trials of the TPF regimen are warranted and urgently required.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of  <span class="marker" data-anno-id="0" data-anno-label="P1">alemtuzumab</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">rituximab</span>  , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Pharmacokinetic studies showed that chronic lymphocytic leukemia involving more than 80 % of the bone marrow at study start was associated with lower trough concentrations of alemtuzumab and rituximab , and that higher trough serum concentrations of alemtuzumab were associated with complete bone marrow clearance . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.</u></h4>This study assessed the safety and preliminary efficacy of escalated dose subcutaneous <b style='color:Tomato;'><i>alemtuzumab</i></b> in combination with <b style='color:Tomato;'><i>rituximab</i></b> in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly <b style='color:Tomato;'><i>rituximab</i></b> at 375 mg/m(2) and <b style='color:Tomato;'><i>alemtuzumab</i></b> doses that started at 30 mg three times per week and escalated to weekly dosing over four weeks, culminating with 90 mg weekly. One dose limiting toxicity of a <b style='color:Tomato;'><i>rituximab</i></b> infusion reaction was seen in cohort 2, but the regimen was otherwise well tolerated without evidence of differential toxicity by cohort. The overall response rate by National Cancer Institute-Working Group criteria was 61%, and the rate of complete bone marrow response was 43%, most of whom were negative for minimal residual disease. The addition of CT scan evaluation per International Workshop on Chronic Lymphocytic Leukemia 2008 criteria reduced the overall response rate to 14%. Median overall survival was 35 months, with 12 patients able to proceed to stem cell transplantation. <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>lymphocytic</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>involving</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>start</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>trough</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>alemtuzumab</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We conclude that escalated subcutaneous doses of <b style='color:Tomato;'><i>alemtuzumab</i></b> given weekly are well tolerated and result in excellent bone marrow clearance of chronic lymphocytic leukemia, helping patients to proceed to stem cell transplantation. This study is registered at ClinicalTrials.gov (Identifier:00330252).</div></div></div></div>

<script>
    var coll = document.getElementsByClassName("collapsible");
    var i;

    for (i = 0; i < coll.length; i++) {
        coll[i].addEventListener("click", function () {
            var content = this.nextElementSibling;
            console.log(content.style)
            if (content.style.display === "block") {
                content.style.display = "none";
            } else {
                content.style.display = "block";
            }
        });
    }
</script>
</body>

</html>